

8. **Tashkin DP**, Elashoff R, Clements PJ, *et al*: Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. *Am J Respir Crit Care Med* 2007;**176**:1026–34.
9. **Thannickal VJ**, Toews GB, White ES, *et al*: Mechanisms of pulmonary fibrosis. *Ann Rev Med* 2004;**55**:395–417.
10. **Ricciardolo FL**, Sterk PJ, Gaston B, *et al*: Nitric oxide in health and disease of the respiratory system. *Physiol Rev* 2004;**84**:731–65.
11. **Fajac I**, Kahan A, Menkes CJ, *et al*: Increased nitric oxide in exhaled air in patients with systemic sclerosis. *Clin Exp Rheumatol* 1998;**16**:547–52.
12. **Tsoukias NM**, George SC: A two-compartment model of pulmonary nitric oxide exchange dynamics. *J Appl Physiol* 1998;**85**:653–66.
13. **Girgis RE**, Gugnani MK, Abrams J, *et al*: Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. *Am J Respir Crit Care Med* 2002;**165**:1587–91.
14. **Tiev KP**, Cabane J, Aubourg F, *et al*: Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. *Eur Respir J* 2007;**30**:26–30.
15. **Hua-Huy T**, Tiev KP, Chereau C, *et al*: Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis. *J Rheumatol* 2010;**37**:1680–7.
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum* 1980;**23**:581–90.
17. **LeRoy EC**, Black C, Fleischmajer R, *et al*: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. *J Rheumatol* 1988;**15**:202–5.
18. **Miller MR**, Hankinson J, Brusasco V, *et al*: ATS/ERS Task Force. Standardisation of spirometry. *Eur Respir J* 2005;**26**:319–38.
19. **American Thoracic Society, European Respiratory Society**: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J Respir Crit Care Med* 2002;**165**:277–304.
20. **McLaughlin VV**, Archer SL, Badesch DB, *et al*: ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation* 2009;**119**:2250–94.
21. **American Thoracic Society, European Respiratory Society**: ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005;**171**:912–30.
22. **George SC**, Hogman M, Permutt S, *et al*: Modeling pulmonary nitric oxide exchange. *J Appl Physiol* 2004;**96**:831–9.
23. **DeLong ER**, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 1988;**44**:837–45.
24. **Goh NS**, Desai SR, Veeraraghavan S, *et al*: Interstitial lung disease in systemic sclerosis: a simple staging system. *Am J Respir Crit Care Med* 2008;**177**:1248–54.
25. **Bouros D**, Wells AU, Nicholson AG, *et al*: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. *Am J Respir Crit Care Med* 2002;**165**:1581–6.
26. **Paredi P**, Kharitonov SA, Loukides S, *et al*: Exhaled nitric oxide is increased in active fibrosing alveolitis. *Chest* 1999;**115**:1352–6.
27. **Moodley YP**, Laloo UG: Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. *Chest* 2001;**119**:1449–54.
28. **Tiev KP**, Le-Dong NN, Duong-Quy S, *et al*: Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis. *Nitric Oxide* 2009;**20**:200–6.
29. **Tiev KP**, Coste J, Ziani M, *et al*: Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2009;**26**:32–8.
30. **Smith AD**, Cowan JO, Brassett KP, *et al*: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. *N Engl J Med* 2005;**352**:2163–73.
31. **Lehtimäki L**, Kankaanranta H, Saarelainen S, *et al*: Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. *Am J Respir Crit Care Med* 2001;**163**:1557–61.

## Journal club

### Lectin-mediated innate defences are important in limiting disease in influenza

The innate immune system is an important defence against previously unencountered pathogens. It recognises surface glycans through cell-associated and soluble lectin-mediated defences. This study investigates the effect of blocking these defences on antiviral activities and disease severity in influenza infection.

Mice were infected with two influenza viruses that differ in the degree of glycosylation of the surface glycoprotein haemagglutinin. Infection with the poorly glycosylated H1N1 virus PR8 resulted in rapid weight loss and a 100% 5-day mortality, whereas the highly glycosylated PR8 reassortant BJx109 resulted in no significant weight loss and a 0% 10-day mortality. This result was replicated in knockout mice with impaired B and T cell function demonstrating that the innate immune system was sufficient to limit disease.

In vitro only the highly glycosylated BJx109 (H3N2) virus infected airway macrophages to high levels and was neutralised by mouse bronchoalveolar lavage and a soluble lectin present in respiratory secretions. These antiviral activities were blocked through preincubation with the polysaccharide mannan indicating that they are lectin mediated. In vivo, blocking these lectin-mediated defences with intranasal mannan led to increased clinical disease as measured by weight loss and 10-day mortality and increased pathological airway disease as measured by virus titres, immunopathology scoring and bronchoalveolar lavage protein levels. Mannan treatment had no effect on antiviral activities or disease severity in PR8 virus infection.

This study demonstrates that surface glycosylation affects the ability of a virus to evade innate lectin-mediated defences, contributing to the degree of clinical and pathological disease caused.

► **Tate M**, Brooks G, Reading P: Inhibition of lectin-mediated innate host defences in vivo modulates disease severity during influenza virus infection. *Immunol Cell Biol* 2011;**89**:482–91.

#### Neelam Kumar

**Correspondence to** Dr N Kumar, Clinical Infection Unit, St George's Hospital, Blackshaw Road, Tooting, London SW17 0QT, UK; neelamkumar@doctors.org.uk

Published Online First 6 May 2011

Thorax 2012;**67**:163. doi:10.1136/thoraxjnl-2011-200358